Organ-Specific Toxicity Assessment Service for Engineered CAR-T

Online Inquiry

Background Service What We Can Offer Workflow HighlightsFAQs Contact

While CAR-T therapy offers remarkable clinical efficacy, predicting and managing its multi-organ toxicities remains a major translational challenge, often leading to unexpected adverse events and costly preclinical setbacks. Creative Biolabs' Organ-Specific Toxicity Assessment Service for Engineered CAR-T provides a targeted solution to this critical gap. We employ a multi-modal platform integrating advanced LICATS (Local Immune Effector Cell-Associated Toxicity Syndrome) profiling and precise Organ-on-Chip simulations. This allows us to precisely identify, quantify, and differentiate organ-specific damage mechanisms, empowering you to de-risk your CAR-T pipeline, optimize candidate selection, and build a robust safety profile for a successful clinical translation.

Introduction

CAR-T therapy has transformed the treatment of relapsed/refractory hematologic malignancies. However, it induces significant systemic toxicities such as cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS), along with multi-organ damage affecting cardiovascular, hematologic, and nervous systems. These toxicities arise from complex mechanisms including cytokine storms and endothelial injury.

Fig.1 Predictive biomarkers for organ-specific toxicity prevention. (OA Literature) Fig.1 Organ-distinct preventive toxicity monitoring parameters.¹

Organ-Specific Toxicity Assessment Service for Engineered CAR-T at Creative Biolabs

Creative Biolabs offers an integrated analytical platform to detect and quantify the risk of localized inflammatory toxicities, particularly the clinical syndrome LICATS, which are frequently undetected by conventional systemic cytokine monitoring. Our service enables developers of CD19, BCMA, and solid-tumor-directed CAR-T products to characterize "on target, on organ" biological activity within specific tissue microenvironments. The resulting data delivers a clear mechanistic roadmap, empowering you to refine CAR constructs.

What We Can Offer

Our service integrates advanced human-relevant in vitro models with cutting-edge in vivo monitoring technologies to deliver a comprehensive and predictive assessment of CAR-T cell organ-specific toxicity.

Featured services of organ-specific toxicity assessment for engineered CAR-T at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials: To commence the toxicity profiling, please submit a sample of the final engineered CAR-T cell product or its genetic construct (viral vector or mRNA sequence). If available, primary B cell or disease relevant target cell samples from the specific autoimmune or oncological patient population under investigation are also requested to ensure model physiological relevance.

Key Steps:

Workflow of organ-specific toxicity assessment for engineered CAR-T at Creative Biolabs. (Creative Biolabs Original)

Estimated Timeframe: The standard delivery timeline for this service spans 6 to 10 weeks, with the exact duration contingent upon the complexity of the requested organ-on-chip model configuration and the required depth of analysis for sequencing.

Key Advantages

Integrated Preclinical Safety Platform: We provide a complete workflow from small scale pilot modeling to high throughput preclinical screening, enabling seamless progression from candidate selection to validation.
Disease-Specific Modeling Expertise: Our protocols are fully customizable to address your unique therapeutic target, whether assessing toxicities in rare autoimmune disease contexts or modeling the complexities of specific solid tumor microenvironments.
Reliable & Standardized Data Output: We ensure platform stability and high reproducibility across multi-organ chip systems, delivering robust and consistent datasets that meet rigorous regulatory submission standards.

FAQs

Q1: Can Organ-on-Chip models be tailored for specific disease mechanisms or therapeutic contexts?

A1: Yes. Our platform supports customization for disease specific modeling and therapeutic contexts. In addition to standard offerings like Blood Brain Barrier (BBB), Heart-on-Chip, Lung-on-Chip, and Liver-on-Chip, we engineer disease relevant conditions, such as introducing inflammatory cytokines, hypoxic environments, or patient derived cells, to better recapitulate pathological microenvironments. This enables physiologically relevant assessment of target engagement, off target effects, and organ-specific inflammatory responses aligned with your therapeutic's intended application.

Q2: Is the service compatible with evaluating novel CAR-T delivery systems, such as nanoparticles or LNPs?

A2: Absolutely. We have optimized protocols for assessing advanced CAR-T delivery platforms, including lipid nanoparticles (LNPs) and viral or non-viral vectors. Our assays evaluate key safety parameters such as organ-specific biodistribution, carrier-induced immunogenicity, localized CAR transgene expression kinetics, and potential vector related toxicities, providing a comprehensive preclinical profile to de-risk complex delivery strategies before clinical translation.

Why Choose Us?

Creative Biolabs pioneers the "bedside-to-bench" translational approach by directly incorporating clinical observations into our investigative platform. We specialize in deciphering the localized inflammatory responses (termed LICATS), a critical yet often overlooked adverse event affecting a significant majority of autoimmune CAR-T recipients. Our focused expertise enables the detection of organ-specific toxicities that conventional screening methods routinely miss, providing unparalleled insights for safer therapeutic development.

Customer Reviews

"Incorporating Creative Biolabs' toxicity assessment into our research has substantially enhanced our capacity to differentiate systemic Cytokine Release Syndrome (CRS) from localized ICANS. The oligodendrocyte derived cell free DNA markers provided a critical 4-day predictive lead, which was instrumental in validating our safety switch mechanism."

— Dr. Jon S.*.

"Integrating the Liver Inflammation and Cardiotoxicity profiling data into our autoimmune CAR-T program streamlined our regulatory interactions. The clear demonstration that the observed organ-specific inflammation was both self-limiting and on-target provided the confidence needed to advance our candidate."

— Sarah M.*.

"Utilizing the platform for nanoparticle-mediated in vivo CAR-T delivery systems has greatly expedited our preclinical safety evaluation. The model's simulation of the alveolar interface was exceptionally faithful to the clinical manifestations later observed."

— Prof. Rrt K.*.

How to Contact Us?

De-risk your CAR-T candidates with human-predictive organ safety data. To schedule a personalized consultation or request a custom project proposal, contact our dedicated scientific team. We are ready to help you confidently advance your lead assets.

Reference

Li, Jingxian et al. "Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention." Frontiers in immunology vol. 15 1422591. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1422591.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.